10-Q Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 Q2 2023

Filing Information

Form Type	10-Q
Accession Number	`0001628280-23-014856`
Period End Date	20230331
Filing Date	20230502
Fiscal Year	2023
Fiscal Period	Q2
XBRL Instance	arwr-20230331_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 84 Cash Flow Statement 56 Stockholders Equity 37

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	290.00M	shares	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	105.96M	shares	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$134.96M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	106.87M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.41M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$69.43M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	106.87M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	105.96M	shares	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$268.39M	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$346.05M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$7.29M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$9.94M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$20.20M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$14.44M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$574.81M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$405.30M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$110.30M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$185.23M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$11.11M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$11.96M	USD	Point-in-time
Long-term investments	`HeldToMaturitySecuritiesNoncurrent`	$105.87M	USD	Point-in-time
Long-term investments	`HeldToMaturitySecuritiesNoncurrent`	$78.83M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$41.11M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$58.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$210.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$218.00K	USD	Point-in-time
Total Assets	`Assets`	$891.31M	USD	Point-in-time
Total Assets	`Assets`	$691.94M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$9.56M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.87M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$46.86M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$39.55M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$5.49M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$12.25M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$2.71M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$2.78M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$29.84M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$74.10M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$87.15M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$138.85M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$78.80M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$80.07M	USD	Point-in-time
Deferred revenue, net of current portion	`ContractWithCustomerLiabilityNoncurrent`	$55.95M	USD	Point-in-time
Deferred revenue, net of current portion	`ContractWithCustomerLiabilityNoncurrent`	$1.07M	USD	Point-in-time
Liability related to the sale of future royalties	`RoyaltiesLiabilityNoncurrent`	-	USD	Point-in-time
Liability related to the sale of future royalties	`RoyaltiesLiabilityNoncurrent`	$257.91M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$134.75M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$339.05M	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value: Authorized 290,000 and 145,000 shares; issued and outstanding 106,869 and 105,960 shares	`CommonStockValue`	$198.00K	USD	Point-in-time
Common stock, $0.001 par value: Authorized 290,000 and 145,000 shares; issued and outstanding 106,869 and 105,960 shares	`CommonStockValue`	$199.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.26B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.22B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-332.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-136.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-813.40M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-820.75M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders equity	`StockholdersEquity`	$398.52M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders equity	`StockholdersEquity`	$446.77M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$19.82M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$18.33M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$372.56M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$452.27M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$465.11M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$396.37M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$891.31M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$691.94M	USD	Point-in-time

Income Statement 84 line items

Line Item	Tag	Value	Unit	Period
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$146.27M	USD	1 Quarter
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$179.24M	USD	2 Qtrs
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$208.81M	USD	2 Qtrs
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$151.81M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$141.75M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$74.88M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$75.98M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$158.58M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$59.26M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$34.27M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$23.22M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$44.21M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$98.10M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$110.25M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$202.78M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$201.01M	USD	2 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$-21.77M	USD	2 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$41.55M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$48.16M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$6.03M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterestAndDividend`	$7.24M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterestAndDividend`	$1.05M	USD	1 Quarter
Interest income	`InvestmentIncomeInterestAndDividend`	$2.21M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterestAndDividend`	$4.56M	USD	1 Quarter
Interest expense	`InterestExpense`	$7.91M	USD	2 Qtrs
Interest expense	`InterestExpense`	-	USD	2 Qtrs
Interest expense	`InterestExpense`	-	USD	1 Quarter
Interest expense	`InterestExpense`	$5.06M	USD	1 Quarter
Other, net	`OtherNonoperatingIncomeExpense`	$515.00K	USD	2 Qtrs
Other, net	`OtherNonoperatingIncomeExpense`	$8.00K	USD	1 Quarter
Other, net	`OtherNonoperatingIncomeExpense`	$1.05M	USD	2 Qtrs
Other, net	`OtherNonoperatingIncomeExpense`	$1.76M	USD	1 Quarter
Total other (loss) income	`NonoperatingIncomeExpense`	$2.81M	USD	1 Quarter
Total other (loss) income	`NonoperatingIncomeExpense`	$3.26M	USD	2 Qtrs
Total other (loss) income	`NonoperatingIncomeExpense`	$-149.00K	USD	2 Qtrs
Total other (loss) income	`NonoperatingIncomeExpense`	$-489.00K	USD	1 Quarter
Income (loss) before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$47.68M	USD	1 Quarter
Income (loss) before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.88M	USD	2 Qtrs
Income (loss) before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$44.37M	USD	1 Quarter
Income (loss) before income tax expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-18.51M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$17.00K	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Net income (loss) including noncontrolling interest	`ProfitLoss`	$47.68M	USD	1 Quarter
Net income (loss) including noncontrolling interest	`ProfitLoss`	$-18.51M	USD	2 Qtrs
Net income (loss) including noncontrolling interest	`ProfitLoss`	$5.87M	USD	2 Qtrs
Net income (loss) including noncontrolling interest	`ProfitLoss`	$44.37M	USD	1 Quarter
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.49M	USD	2 Qtrs
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	$-999.00K	USD	1 Quarter
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	2 Qtrs
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$48.67M	USD	1 Quarter
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-41.33M	USD	1 Quarter
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-62.87M	USD	1 Quarter
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$7.35M	USD	2 Qtrs
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$44.37M	USD	1 Quarter
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-18.51M	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$-0.18	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.07	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.46	USD	1 Quarter
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.42	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.07	USD	2 Qtrs
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.41	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-0.18	USD	2 Qtrs
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.45	USD	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	106.76M	shares	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	106.39M	shares	2 Qtrs
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	105.55M	shares	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	105.03M	shares	2 Qtrs
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	105.03M	shares	2 Qtrs
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	107.93M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	108.14M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	107.89M	shares	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-38.00K	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-39.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-74.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-122.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-196.00K	USD	2 Qtrs
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$47.60M	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$5.67M	USD	2 Qtrs
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$44.37M	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-18.54M	USD	2 Qtrs

Cash Flow Statement 56 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$47.68M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-18.51M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$5.87M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$44.37M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$58.31M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$40.00M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$5.17M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$5.36M	USD	2 Qtrs
(Accretion) amortization of note premiums/discounts	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$82.00K	USD	2 Qtrs
(Accretion) amortization of note premiums/discounts	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-329.00K	USD	2 Qtrs
Non-cash interest expense on liability related to the sale of future royalties	`NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties`	-	USD	2 Qtrs
Non-cash interest expense on liability related to the sale of future royalties	`NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties`	$7.91M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-8.94M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$68.02M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-20.31M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$3.31M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.15M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$6.69M	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-27.28M	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$3.70M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-99.14M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-54.93M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$580.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$1.21M	USD	2 Qtrs
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-107.19M	USD	2 Qtrs
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.42M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$66.22M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$10.53M	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireInvestments`	$192.53M	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireInvestments`	$148.39M	USD	2 Qtrs
Proceeds from maturities of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$141.99M	USD	2 Qtrs
Proceeds from maturities of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$55.78M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-116.76M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-103.14M	USD	2 Qtrs
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$3.73M	USD	2 Qtrs
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$1.10M	USD	2 Qtrs
Proceeds from the sale of future royalties	`ProceedsFromContributedCapital`	-	USD	2 Qtrs
Proceeds from the sale of future royalties	`ProceedsFromContributedCapital`	$250.00M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$251.10M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.73M	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-97.99M	USD	2 Qtrs
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$27.15M	USD	2 Qtrs
Effect of exchange rate on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-38.00K	USD	2 Qtrs
Effect of exchange rate on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-196.00K	USD	2 Qtrs
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.00M	USD	Point-in-time
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$184.43M	USD	Point-in-time
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$86.41M	USD	Point-in-time
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$134.96M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$108.00M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$184.43M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$86.41M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$134.96M	USD	Point-in-time
Interest paid	`InterestPaidNet`	-	USD	2 Qtrs
Interest paid	`InterestPaidNet`	-	USD	2 Qtrs
Income taxes (paid) refunded	`IncomeTaxesPaidNet`	-	USD	2 Qtrs
Income taxes (paid) refunded	`IncomeTaxesPaidNet`	-	USD	2 Qtrs

Stockholders Equity 37 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$372.56M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$452.27M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$465.11M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$396.37M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$19.39M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$20.61M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$24.50M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$33.80M	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.54M	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$520.00K	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.15M	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$576.00K	USD	1 Quarter
Exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	145,637.00	shares	2 Qtrs
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	1 Quarter
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-38.00K	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-39.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-74.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-122.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-196.00K	USD	2 Qtrs
Interest in joint venture	`MinorityInterestDecreaseFromRedemptions`	$999.00K	USD	1 Quarter
Interest in joint venture	`MinorityInterestDecreaseFromRedemptions`	$486.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$48.67M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-41.33M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-62.87M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$7.35M	USD	2 Qtrs
Net income (loss)	`NetIncomeLoss`	$44.37M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-18.51M	USD	2 Qtrs
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$372.56M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$452.27M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$465.11M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$408.82M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$396.37M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.